

References

St. John's Wort

- Murch SJ, Simmons CB, Saxena PK. Melatonin in feverfew and other medicinal plants. *Lancet* 1997;350:1598-9. [View abstract.](#) **50**
- Miller LG. Herbal Medicinals: Selected clinical considerations focusing on known or potential drug-herb interactions. *Arch Intern Med* 1998;158:2200-11. [View abstract.](#) **166**
- Bennett DA Jr, Phun L, Polk JF, et al. Neuropharmacology of St. John's Wort (*Hypericum*). *Ann Pharmacother* 1998;32:1201-8. [View abstract.](#) **167**
- Vorbach EU, Arnoldt KH, Hubner WD. Efficacy and tolerability of St. John's wort extract LI 160 versus imipramine in patients with severe depressive episodes according to ICD- 10. *Pharmacopsychiatry* 1997;30:81-5. [View abstract.](#) **203**
- Wheatley D. LI 160, an extract of St. John's wort, versus amitriptyline in mildly to moderately depressed outpatients - a controlled 6-week clinical trial. *Pharmacopsychiatry* 1997;30:77-80. [View abstract.](#) **204**
- Volz HP. Controlled clinical trials of hypericum extracts in depressed patients - an overview. *Pharmacopsychiatry* 1997;30 Suppl 2:72-6. [View abstract.](#) **205**
- Gulick RM, McAuliffe V, Holden-Wiltse J, et al. Phase I studies of hypericin, the active compound in St. John's Wort, as an antiretroviral agent in HIV-infected adults. AIDS Clinical Trials Group Protocols 150 and 258. *Ann Intern Med* 1999;130:510-4. [View abstract.](#) **206**
- O'Breasail AM, Argouarch S. Hypomania and St John's wort. *Can J Psychiatry* 1998;43:746-7. [View abstract.](#) **325**
- Hubner WD, Lande S, Podzuweit H. Hypericum treatment of mild depressions with somatic symptoms. *J Geriatr Psychiatry Neurol* 1994;7 Suppl 1:S12-4. [View abstract.](#) **376**
- Johne A, Brockmoller J, Bauer S, et al. Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (*Hypericum perforatum*). *Clin Pharmacol Ther* 1999;66:338-45. [View abstract.](#) **382**
- Anon. A better treatment for depression? *UC Berkeley Wellness Letter* 1997;13:1-2. **394**
- Gordon JB. SSRIs and St. John's Wort: possible toxicity? *Am Fam Physician* 1998;57:950, 953. [View abstract.](#) **542**
- Golsch S, Vocks E, Rakoski J, et al. [Reversible increase in photosensitivity to UV-B caused by St. John's wort extract]. *Hautarzt* 1997;48:249-52. [View abstract.](#) **620**
- Bove GM. Acute neuropathy after exposure to sun in a patient treated with St. John's Wort. *Lancet* 1998;352:1121-2. [View abstract.](#) **621**
- Brockmoller J, Reum T, Bauer S, et al. Hypericin and pseudohypericin: pharmacokinetics and effects on photosensitivity in humans. *Pharmacopsychiatry* 1997;30:94-101. [View abstract.](#) **628**
- Upton R, ed. St. John's wort, *Hypericum perforatum*: Quality control, analytical and therapeutic monograph. Santa Cruz, CA: American Herbal Pharmacopoeia 1997;1-32. **758**
- Chavez ML, Chavez PI. Saint John's wort. *Hosp Pharm* 1997;32:1621-32. **759**

- Laakmann G, Schule C, Baghai T, Kieser M. St. John's wort in mild to moderate depression: the relevance of hyperforin for the clinical efficacy. *Pharmacopsych* 1998;31:54-9. [View abstract.](#) **761**
- Chatterjee SS, Noldner M, Koch E, Erdelmeier C. Antidepressant activity of hypericum perforatum and hyperforin: the neglected possibility. *Pharmacopsych* 1998;31:7-15. [View abstract.](#) **762**
- Muller WE, Singer A, Wonnemann M, et al. Hyperforin represents the neurotransmitter reuptake inhibiting constituent of hypericum extract. *Pharmacopsychiatry* 1998;31:16-21. [View abstract.](#) **763**
- Abul-Ezz SR, Barone GW, Gurley BJ, et al. Effect of herbal supplements on cyclosporine blood levels and associated acute rejection. *Am Soc of Nephrol Ann Mtg, Toronto, CAN* 2000;Oct. 11-16:abstract A3754. **1234**
- Hussain MD, Teixeira MG. Saint John's wort and analgesia: effect of Saint John's wort on morphine induced analgesia. *AAPS Ann Mtg & Expo Indianapolis, IN:2000;Oct 29- Nov 2:presentation #3453.* **1279**
- Piscitelli SC, Burstein AH, Chait D, et al. Indinavir concentrations and St John's wort. *Lancet* 2000;355:547-8. [View abstract.](#) **1290**
- Yue QY, Bergquist C, Gerden B. Safety of St. John's wort (*Hypericum perforatum*). *Lancet* 2000;355:576-7. [View abstract.](#) **1292**
- Ruschitzka F, Meier PJ, Turina M, et al. Acute heart transplant rejection due to Saint John's wort. *Lancet* 2000;355:548-9. [View abstract.](#) **1293**
- Roberts JE, Wang RH, Tan IP, et al. Hypericin (active ingredient in St. John's wort) photo-oxidation of lens proteins. *Photochem Photobiol* 1999;69:42S. **1296**
- Gurley BJ, Barone GW. Herb-drug interaction involving St. John's wort and cyclosporine. *AAPS Ann Mtg & Expo Indianapolis, IN:2000;Oct 29- Nov 2: presentation #3443.* **1301**
- Gurley BJ, Gardner SF, Hubbard MA. Clinical assessment of potential cytochrome P450-mediated herb-drug interactions. *AAPS Ann Mtg & Expo Indianapolis, IN: 2000; Oct 29 - Nov 2:presentation #3460.* **1303**
- Durr D, Stieger B, Kullak-Ublick GA, et al. St. John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. *Clin Pharmacol Ther* 2000;68:598-604. [View abstract.](#) **1340**
- Lee A, Minhas R, Ito S, et al. Safety of St. John's wort during breastfeeding. *Clin Pharmacol Ther* 2000;67:130, abstract PII-64. **1377**
- Roots I, Johne A, Schmider J, Brockmoller J, et al. Interaction of a herbal extract from St. John's wort with amitriptyline and its metabolites. *Clin Pharmacol Ther* 2000;67:159, abstract PIII-69. **1378**
- Schneck C. St. John's wort and hypomania. *J Clin Psychiatry* 1998;59:689. [View abstract.](#) **3524**
- Schempp CM, Winghofer B, Langheinrich M, et al. Hypericin levels in human serum and interstitial skin blister fluid after oral single-dose and steady state administration of *Hypericum perforatum* extract (St. John's Wort). *Skin Pharmacol Appl Skin Physiol* 1999;12:299-304. [View abstract.](#) **3547**
- Kim HL, Streltzer J, Goebert D. St. John's wort for depression: A meta analysis of well-defined clinical trials. *J Nerv Ment Dis* 1999;187:532-9.[View abstract.](#) **3548**

- 3549**
- Linde K, Ramirez G, Mulrow CD, et al. St. John's wort for depression: an overview and meta-analysis of randomized clinical trials. *BMJ* 1996;313:253-8. [View abstract.](#)
- 3550**
- Harrer G, Schmidt U, Kuhn U, Biller A. Comparison of equivalence between the St. John's wort extract LoHyp-57 and fluoxetine. *Arzneimittelforschung* 1999;49:289-96. [View abstract.](#)
- 3551**
- Philipp M, Kohnen R, Hiller KO. Hypericum extract versus imipramine or placebo in patients with moderate depression: randomized multicentre study of treatment for eight weeks. *BMJ* 1999;319:1534-9. [View abstract.](#)
- 3552**
- Gaster B, Holroyd J. St John's wort for depression. *Arch Intern Med* 2000;160:152-6. [View abstract.](#)
- 3553**
- Singer A, Wonnemann M, Muller WE. Hyperforin, a major antidepressant constituent of St. John's wort, inhibits serotonin uptake by elevating free intracellular Na⁺. *J Pharmacol Exp Ther* 1999;290:1363-8. [View abstract.](#)
- 3554**
- Schempp C, Pelz K, Wittmer A, et al. Antibacterial activity of hyperforin from St. John's wort, against multiresistant *Staphylococcus aureus* and gram-positive bacteria. *Lancet* 1999;353:2129. [View abstract.](#)
- 3555**
- Nierenberg AA, Burt T, Matthews J, et al. Mania associated with St. John's wort. *Biol Psychiatry* 1999;46:1707-8. [View abstract.](#)
- 3556**
- Nebel A, Schneider BJ, Baker RA, et al. Potential metabolic interaction between St. John's wort and theophylline. *Ann Pharmacother* 1999;33:502. [View abstract.](#)
- 3568**
- Moses EL, Mallinger AG. St. John's wort: Three cases of possible mania induction. *J Clin Psychopharmacol* 2000;20:115-7. [View abstract.](#)
- 3569**
- Beckman SE, Sommi RW, Switzer J. Consumer use of St. John's wort: A survey of effectiveness, safety, and tolerability. *Pharmacotherapy* 2000;20:568-74. [View abstract.](#)
- 3570**
- Ereshefsky B, Gewertz N, Lam YMF, et al. Determination of SJW differential metabolism at CYP2D6 and CYP3A4, using dextromethorphan probe methodology. Abstract Poster Presentations, 39th NCDEU Annual Meeting, 1999:Poster 130 128.
- 3571**
- Gewertz N, Ereshefsky B, Lam YWF, et al. Determination of the differential effects of St. John's wort on the CYP1A2 and NAT2 metabolic pathways using caffeine probe methodology. Abstract Poster Presentations, 39th NCDEU Annual Meeting, 1999:Poster 131.
- 3599**
- Markowitz JS, DeVane CL, Boulton DW, et al. Effect of St. John's wort (*Hypericum perforatum*) on cytochrome P-450 2D6 and 3A4 activity in healthy volunteers. *Life Sci* 2000;66:PL 133-9. [View abstract.](#)
- 3900**
- Peirce A. *The American Pharmaceutical Association Practical Guide to Natural Medicines*. New York, NY: William Morrow and Co., 1999.
- 4239**
- Ondrizek RR, Chan PJ, Patton WC, King A. Inhibition of human sperm motility by specific herbs used in alternative medicine. *J Assist Reprod Genet* 1999;16:87-91. [View abstract.](#)
- 4240**
- Ondrizek RR, Chan PJ, Patton WC, King A. An alternative medicine study of herbal effects on the penetration of zona-free hamster oocytes and the integrity of sperm deoxyribonucleic acid. *Fertil Steril* 1999;71:517-22. [View abstract.](#)
- 4513**

- Mai I, Kruger H, Budde K, et al. Hazardous pharmacokinetic interaction of Saint John's wort (*Hypericum perforatum*) with the immunosuppressant cyclosporin. *Int J Clin Pharmacol Ther* 2000;38:500-2. [View abstract](#). **4518**
- Whiskey E, Werneke U, Taylor D. A systematic review and meta-analysis of *Hypericum perforatum* in depression: a comprehensive clinical review. *Int Clin Psychopharmacol* 2001;16:239-52. [View abstract](#). **4520**
- Jakovljevic V, Popovic M, Mimica-Dukic N, et al. Pharmacodynamic study of *Hypericum perforatum* L. *Phytomedicine* 2000;7:449-53. [View abstract](#). **4521**
- Jensen AG, Hansen SH, Nielsen EO. Adhyperforin as a contributor to the effect of *Hypericum perforatum* L. in biochemical models of antidepressant activity. *Life Sci* 2001;68:1593-605. [View abstract](#). **4538**
- Hubner WD, Kirste T. Experience with St. John's Wort (*Hypericum perforatum*) in children under 12 years with symptoms of depression and psychovegetative disturbances. *Phytother Res* 2001;15:367-70. [View abstract](#). **4542**
- Schempp CM, Muller K, Winghofer B, et al. Single-dose and steady-state administration of *Hypericum perforatum* extract (St. John's wort) does not influence skin sensitivity to UV radiation, visible light, and solar-stimulated radiation. *Arch Dermatol* 2001;137:512-3. [View abstract](#). **4628**
- Schempp CM, Ludtke R, Winghofer B, Simon JC. Effect of topical application of hypericum *perforatum* extract on skin sensitivity to solar simulated radiation. *Photodermatol Photoimmunol Photomed* 2000;16:125-8. [View abstract](#). **4629**
- Shan MD, Hu LH, Chen ZL. Three new hyperforin Analogues from *Hypericum perforatum*. *J Nat Prod* 2001;664:127-30. [View abstract](#). **4630**
- Laakmann G, Dienel A, Kieser M. Clinical significance of hyperforin for the efficacy of *Hypericum* extracts on depressive disorders of different severities. *Phytomedicine* 1998;6:435-42. **4631**
- Jacobson JM, Feinman L, Liebes L, et al. Pharmacokinetics, safety, and antiviral effects of hypericin, a derivative of St. John's Wort plant, in patients with chronic hepatitis C virus infection. *Antimicrob Agents Chemother* 2001;45:517-24. [View abstract](#). **4632**
- Khalifa AE. *Hypericum perforatum* as a nootropic drug: enhancement of retrieval memory of a passive avoidance conditioning paradigm in mice. *J Ethnopharmacol* 2001;76:49-57. [View abstract](#). **4826**
- Moschella C, Jaber BL. Interaction between cyclosporine and *Hypericum perforatum* (St. John's wort) after organ transplantation. *Amer J Kidney Dis* 2001;38:1105-7. [View abstract](#). **4831**
- Karliova M, Treichel U, Malago M, et al. Interaction of *Hypericum perforatum* (SJW) with cyclosporin A metabolism in a patient after liver transplantation. *J Hepatol* 2000;33:853-5. [View abstract](#). **4834**
- Mandelbaum A, Pertzborn F, Martin-Facklam M, Wiesel M. Unexplained decrease of cyclosporin trough levels in a compliant renal transplant patient. *Nephrol Dial Transplant* 2000;15:1473-4. [View abstract](#). **4835**
- Wang Z, Gorski JC, Hamman MA, et al. The effects of St. John's wort (*Hypericum perforatum*) on human cytochrome P450 activity. *Clin Pharmacol Ther* 2001;70:317-26. [View abstract](#). **4836**
- Assalian P. Sildenafil for SJW-induced sexual dysfunction. *J Sex Marital Ther* 2000;26:357-8. [View abstract](#).

- de Maat M, Hoetelmans R, Mathot R, et al. Drug interaction between St. John's wort and nevirapine. *AIDS* 2001;15:420-1. [View abstract.](#) **4837**
- Richter O. Several countries issue restrictions on St. John's wort. *Richter's HerbLetter* 7/30/00. Available at: www.richters.com (Accessed 01 March 2002). **4892**
- Schrader E. Equivalence of St. John's wort extract (Ze 117) and fluoxetine: a randomized, controlled study in mild-moderate depression. *Int Clin Psychopharmacol* 2000;15:61-8. [View abstract.](#) **4897**
- Linde K, Mulrow CD. St. John's wort for depression. *Cochrane Database Syst Rev* 2000;(2):CD000448. [View abstract.](#) **4899**
- Ernst E, Rand JI, Barnes J, Stevinson C. Adverse effects profile of the herbal antidepressant St. John's wort (*Hypericum perforatum* L.). *Eur J Clin Pharmacol* 1998;54:589-94. [View abstract.](#) **5073**
- Lantz MS, Buchalter E, Giambanco V. St. John's wort and antidepressant drug interactions in the elderly. *J Geriatr Psychiatry Neurol* 1999;12:7-10. [View abstract.](#) **5074**
- Taylor LH, Kobak KA. An open-label trial of St. John's wort (*Hypericum perforatum*) in obsessive-compulsive disorder. *J Clin Psychiatry* 2000;61:575-8. [View abstract.](#) **5075**
- Snow V, Lascher S, Mottur-Pilson C. Pharmacologic treatment of acute major depression and dysthymia. *Ann Intern Med* 2000;132:738-42. [View abstract.](#) **5087**
- Shelton RC, Keller MB, Gelenberg A, et al. Effectiveness of St. John's wort in major depression: A randomized, placebo-controlled trial. *JAMA* 2001;285:1978-86. [View abstract.](#) **5096**
- Laird RD, Webb M. Psychotic episode during use of St. John's wort. *J Herb Pharmacother* 2001;1:81-7. **5249**
- Breidenbach T, Hoffmann MW, Becker T, et al. Drug interaction of St. John's wort with cyclosporin. *Lancet* 2000;355:1912. [View abstract.](#) **6112**
- Rey JM, Walter G. *Hypericum perforatum* (St. John's wort) in depression: pest or blessing? *Med J Aust* 1998;169:583-6. [View abstract.](#) **6200**
- Brown TM. Acute St. John's wort toxicity. *Am J Emerg Med* 2000;18:231-2. [View abstract.](#) **6201**
- Brenner R, Azbel V, Madhusoodanan S, et al. Comparison of an extract of *Hypericum* (LI 160) and sertraline in the treatment of depression: A double-blind, randomized pilot study. *Clin Ther* 2000;22:411-9. [View abstract.](#) **6400**
- Roby CA, Anderson GD, Kantor E, et al. St. John's wort: Effect on CYP3A4 activity. *Clin Pharmacol Ther* 2000;67:451-7. [View abstract.](#) **6425**
- Schempp CM, Winghofer B, Ludtke R, et al. Topical application of St. John's wort (*Hypericum perforatum* L.) and its metabolite hyperforin inhibits the allostimulatory capacity of epidermal cells. *Br J Dermatol* 2000;142:979-84. [View abstract.](#) **6426**
- Kleber E, Obry T, Hippeli S, et al. Biochemical activities of extracts from *Hypericum perforatum* L. 1st Communication: inhibition of dopamine-beta-hydroxylase. *Arzneimittelforschung* 1999;49:106-9. [View abstract.](#) **6427**
- Williams JW, Mulrow CD, Chiquette E, et al. A systematic review of newer pharmacotherapies for depression in adults: Evidence report summary. *Ann Intern Med* 2000;132:743-56. [View abstract.](#) **6428**

- 6429**
- Stevinson C, Ernst E. A pilot study of Hypericum perforatum for the treatment of premenstrual syndrome. *BJOG* 2000;107:870-6. [View abstract.](#)
- 6434**
- Woelk H. Comparison of St. John's wort and imipramine for treating depression: randomized controlled trial. *BMJ* 2000;321:536-9. [View abstract.](#)
- 6435**
- Barone GW, Gurley BJ, Ketel BL, et al. Drug interaction between St. John's wort and cyclosporin. *Ann Pharmacother* 2000;34:1013-6. [View abstract.](#)
- 6463**
- Moore LB, Goodwin B, Jones SA, et al. St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. *Proc Natl Acad Sci U S A* 2000;97:7500-2. [View abstract.](#)
- 6473**
- Cheng TO. St. John's wort interaction with digoxin [letter]. *Arch Intern Med* 2000;160:2548. [View abstract.](#)
- 6474**
- Vormfelde SV, Poser W. Hyperforin in extracts of St. John's wort (*Hypericum perforatum*) for depression [letter]. *Arch Intern Med* 2000;160:2548-9. [View abstract.](#)
- 6475**
- Wentworth JM, Agostini M, Love J, et al. St. John's wort, a herbal antidepressant, activates the steroid X receptor. *J Endocrinol* 2000;166:R11-6. [View abstract.](#)
- 6477**
- Lane-Brown MM. Photosensitivity associated with herbal preparations of St. John's wort (*Hypericum perforatum*). *Med J Aust* 2000;172:302. [View abstract.](#)
- 6478**
- Lal S, Iskandar H. St. John's wort and schizophrenia. *CMAJ* 2000;163:262-3. [View abstract.](#)
- 7047**
- Sindrup SH, Madsen C, Bach FW, et al. St. John's wort has no effect on pain in polyneuropathy. *Pain* 2000;91:361-5. [View abstract.](#)
- 7092**
- Mathijssen RHJ, Verweij J, De Bruijn P, et al. Modulation of irinotecan (CPT-11) metabolism by St. John's wort in cancer patients. American Association for Cancer Research Annual Meeting, San Francisco, April 2002. Abstract 2443.
- 7095**
- Mai I, Bauer S, Krueger H, et al. Wechselwirkungen von Johanniskraut mit Tacrolimus bei nierentransplantierten Patienten. Symposium Phytopharmaka VII. Forschung und Klinische Anwendung, Berlin, October, 2001.
- 7312**
- Bhopal JS. St John's wort-induced sexual dysfunction. *Can J Psychiatry* 2001;46:456-457. [View abstract.](#)
- 7404**
- Sultana D, Peindl KS, Wisner KL. Rash associated with St. John's wort treatment in premenstrual dysphoric disorder. *Arch Women Ment Health* 2000;3:99-101.
- 7807**
- de los Reyes GC, Koda RT. Determining hyperforin and hypericin content in eight brands of St. John's wort. *Am J Health Syst Pharm* 2002;59:545-7. [View abstract.](#)
- 7808**
- Schulz V. Incidence and clinical relevance of the interactions and side effects of *Hypericum* preparations. *Phytomedicine* 2001;8:152-60. [View abstract.](#)
- 7809**
- Gorski JC, Hamman MA, Wang Z, et al. The effect of St. John's wort on the efficacy of oral contraceptives (abstract MPI-80). *Clin Pharmacol Ther* 2001;71:P25.
- 7810**
- Hennessy M, Kelleher D, Spiers JP, et al. St John's wort increases expression of P-glycoprotein: implications for drug interactions. *Br J Clin Pharmacol* 2002;53:75-82. [View abstract.](#)
- 7811**

- Parker V, Wong AH, Boon HS, Seeman MV. Adverse reactions to St John's Wort. *Can J Psychiatry* 2001;46:77-9. [View abstract](#). **7812**
- Patel S, Robinson R, Burk M. Hypertensive crisis associated with St. John's Wort. *Am J Med* 2002;112:507-8. [View abstract](#). **8056**
- Singhal AB, Caviness VS, Begleiter AF, et al. Cerebral vasoconstriction and stroke after use of serotonergic drugs. *Neurology* 2002;58:130-3. [View abstract](#). **8569**
- Ferko N, Levine MA. Evaluation of the association between St. John's wort and elevated thyroid-stimulating hormone. *Pharmacotherapy* 2001;21:1574-8. [View abstract](#). **8570**
- Hauben M. The association of St. John's wort with elevated thyroid-stimulating hormone. *Pharmacotherapy* 2002;22:673-5. [View abstract](#). **8582**
- Spinella M, Eaton LA. Hypomania induced by herbal and pharmaceutical psychotropic medicines following mild traumatic brain injury. *Brain Inj* 2002;16:359-67. [View abstract](#). **8930**
- Holme SA, Roberts DL. Erythroderma associated with St John's wort. *Br J Dermatol* 2000;143:1127-8. [View abstract](#). **8931**
- Irefin S, Sprung J. A possible cause of cardiovascular collapse during anesthesia: long-term use of St. John's Wort. *J Clin Anesth* 2000;12:498-9. [View abstract](#). **8932**
- Kumar V, Jaiswal AK, Singh PN, Bhattacharya SK. Anxiolytic activity of Indian *Hypericum perforatum* Linn: an experimental study. *Indian J Exp Biol* 2000;38:36-41. [View abstract](#). **8933**
- Martonfi P, Repcak M, Ciccarelli D, Garbari F. *Hypericum perforatum* L. - chemotype without rutin from Italy. *Biochem Syst Ecol* 2001;29:659-61. [View abstract](#). **8934**
- Southwell IA, Bourke CA. Seasonal variation in hypericin content of *Hypericum perforatum* L. (St. John's Wort). *Phytochemistry* 2001;56:437-41. [View abstract](#). **8935**
- Bilia AR, Bergonzi MC, Morgenni F, et al. Evaluation of chemical stability of St. John's wort commercial extract and some preparations. *Int J Pharm* 2001;213:199-208. [View abstract](#). **8936**
- Calapai G, Crupi A, Firenzuoli F, et al. Serotonin, norepinephrine and dopamine involvement in the antidepressant action of *hypericum perforatum*. *Pharmacopsychiatry* 2001;34:45-9. [View abstract](#). **9204**
- Henderson L, Yue QY, Bergquist C, et al. St John's wort (*Hypericum perforatum*): drug interactions and clinical outcomes. *Br J Clin Pharmacol* 2002;54:349-56. [View abstract](#). **9205**
- Schempp CM, Kirkin V, Simon-Haarhaus B, et al. Inhibition of tumour cell growth by hyperforin, a novel anticancer drug from St. John's wort that acts by induction of apoptosis. *Oncogene* 2002;21:1242-50. [View abstract](#). **9206**
- Mathijssen RH, Verweij J, de Bruijn P, et al. Effects of St. John's wort on irinotecan metabolism. *J Natl Cancer Inst* 2002;94:1247-9. [View abstract](#). **9474**
- Ladner DP, Klein SD, Steiner RA, Walt H. Synergistic toxicity of delta-aminolaevulinic acid-induced protoporphyrin IX used for photodiagnosis and *hypericum* extract, a herbal antidepressant. *Br J Dermatol* 2001;144:916-8. [View abstract](#). **9476**
- Volz HP, Murck H, Kasper S, Moller HJ. St John's wort extract (LI 160) in somatoform disorders: results of a placebo-controlled trial. *Psychopharmacology (Berl)* 2002;164:294-300. [View abstract](#).

- Ernst E. St. John's Wort supplements endanger the success of organ transplantation. *Arch Surg* 2002;137:316-9. [View abstract.](#) **9596**
- Kasper S, Dienel A. Cluster analysis of symptoms during antidepressant treatment with Hypericum extract in mildly to moderately depressed out-patients. A meta-analysis of data from three randomized, placebo-controlled trials. *Psychopharmacology (Berl)* 2002;164:301-8. [View abstract.](#) **9597**
- Wang Z, Hamman MA, Huang SM, et al. Effect of St. John's wort on the pharmacokinetics of fexofenadine. *Clin Pharmacol Ther* 2002;71:414-20.. [View abstract.](#) **9685**
- Wheatley D. Hypericum in seasonal affective disorder (SAD). *Curr Med Res Opin* 1999;15:33-7. [View abstract.](#) **9686**
- Chan LY, Chiu PY, Lau TK. A study of hypericin-induced teratogenicity during organogenesis using a whole rat embryo culture model. *Fertil Steril* 2001;76:1073-4. [View abstract.](#) **9687**
- Schwarz UI, Buschel B, Kirch W. Unwanted pregnancy on self-medication with St John's wort despite hormonal contraception. *Br J Clin Pharmacol* 2003;55:112-3. [View abstract.](#) **9880**
- Anon. Final report on the safety assessment of Hypericum perforatum extract and Hypericum perforatum oil. *Int J Toxicol* 2001;20:31-9. [View abstract.](#) **9881**
- Logan JL, Ahmed J. Critical hypokalemic renal tubular acidosis due to Sjogren's syndrome: association with the purported immune stimulant echinacea. *Clin Rheumatol* 2003;22:158-9. [View abstract.](#) **10319**
- Mai I, Stormer E, Bauer S, et al. Impact of St John's wort treatment on the pharmacokinetics of tacrolimus and mycophenolic acid in renal transplant patients. *Nephrol Dial Transplant* 2003;18:819-22.. [View abstract.](#) **10329**
- Groning R, Breitzkreutz J, Muller RS. Physico-chemical interactions between extracts of Hypericum perforatum L. and drugs. *Eur J Pharm Biopharm* 2003;56:231-6.. [View abstract.](#) **10448**
- Sugimoto K, Ohmori M, Tsuruoka S, et al. Different effects of St John's wort on the pharmacokinetics of simvastatin and pravastatin. *Clin Pharmacol Ther* 2001;70:518-24.. [View abstract.](#) **10627**
- Bauer S, Stormer E, Johne A, et al. Alterations in cyclosporin A pharmacokinetics and metabolism during treatment with St John's wort in renal transplant patients. *Br J Clin Pharmacol* 2003;55:203-11.. [View abstract.](#) **10628**
- Markowitz JS, Donovan JL, DeVane CL, et al. Effect of St. John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. *JAMA* 2003;290:1500-4.. [View abstract.](#) **10830**
- Hypericum Depression Trial Study Group. Effect of Hypericum perforatum (St. John's wort) in major depressive disorder: a randomized controlled trial. *JAMA* 2002;287:1807-14. [View abstract.](#) **10843**
- Findling RL, McNamara NK, O'Riordan MA, et al. An open-label pilot study of St. John's wort in juvenile depression. *J Am Acad Child Adolesc Psychiatry* 2003;42:908-914. [View abstract.](#) **10844**
- Hammerness P, Basch E, Ulbricht C, et al. St. John's wort: a systematic review of adverse effects and drug interactions for the consultation psychiatrist. *Psychosomatics* 2003;44:271-82. [View abstract.](#) **10845**
- 10846**

- Rayburn WF, Gonzalez CL, Christensen HD, Stewart JD. Effect of prenatally administered hypericum (St John's wort) on growth and physical maturation of mouse offspring. *Am J Obstet Gynecol* 2001;184:191-5. [View abstract](#). **10847**
- Gurley BJ, Gardner SF, Hubbard MA, et al. Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans. *Clin Pharmacol Ther* 2002;72:276-87.. [View abstract](#). **10848**
- Foster BC, Vandenhoeck S, Hana J, et al. In vitro inhibition of human cytochrome P450-mediated metabolism of marker substrates by natural products. *Phytomedicine* 2003;10:334-42.. [View abstract](#). **10849**
- Draves AH, Walker SE. Analysis of the hypericin and pseudohypericin content of commercially available St John's Wort preparations. *Can J Clin Pharmacol* 2003;10:114-118.. [View abstract](#). **11154**
- Shelton RC. St John's Wort for the treatment of depression. *Lancet Neurol* 2002;1:275. [View abstract](#). **11408**
- Schule C, Baghai T, Ferrera A, Laakmann G. Neuroendocrine effects of Hypericum extract WS 5570 in 12 healthy male volunteers. *Pharmacopsychiatry* 2001;34:S127-33. [View abstract](#). **11490**
- Wilhelm KP, Biel S, Siegers CP. Role of flavonoids in controlling the phototoxicity of Hypericum perforatum extracts. *Phytomedicine* 2001;8:306-9. [View abstract](#). **11722**
- Kim RB. Drugs as P-glycoprotein substrates, inhibitors, and inducers. *Drug Metab Rev* 2002;34:47-54. [View abstract](#). **11800**
- Siepmann M, Krause S, Joraschky P, et al. The effects of St John's wort extract on heart rate variability, cognitive function and quantitative EEG: a comparison with amitriptyline and placebo in healthy men. *Br J Clin Pharmacol* 2002;54:277-82. [View abstract](#). **11801**
- Dean AJ, Moses GM, Vernon JM. Suspected withdrawal syndrome after cessation of St. John's wort. *Ann Pharmacother* 2003;37:150. [View abstract](#). **11802**
- Morimoto T, Kotegawa T, Tsutsumi K, et al. Effect of St. John's wort on the pharmacokinetics of theophylline in healthy volunteers. *J Clin Pharmacol* 2004;44:95-101. [View abstract](#). **11804**
- Bilia AR, Gallori S, Vincieri FF. St. John's wort and depression: efficacy, safety and tolerability-an update. *Life Sci* 2002;70:3077-96. [View abstract](#). **11886**
- Pfrunder A, Schiesser M, Gerber S, et al. Interaction of St John's wort with low-dose oral contraceptive therapy: a randomized controlled trial. *Br J Clin Pharmacol* 2003;56:683-90. [View abstract](#). **11887**
- Hall SD, Wang Z, Huang SM, et al. The interaction between St John's wort and an oral contraceptive. *Clin Pharmacol Ther* 2003;74:525-35. [View abstract](#). **11888**
- Frye RF, Fitzgerald SM, Lagattuta TT, et al. Effect of St. John's wort on imatinib mesylate pharmacokinetics. *Clin Pharmacol Ther* 2004;76:323-9. [View abstract](#). **11889**
- Komoroski BJ, Zhang S, Cai H, et al. Induction and inhibition of cytochromes P450 by the St. John's wort constituent hyperforin in human hepatocyte cultures. *Drug Metab Dispos* 2004;32:512-8. [View abstract](#). **11890**
- Jiang X, Williams KM, Liauw WS, et al. Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. *Br J Clin Pharmacol* 2004;57:592-9. [View abstract](#). **13015**

- Shimizu K, Nakamura M, Isse K, Nathan PJ. First-episode psychosis after taking an extract of *Hypericum perforatum* (St John's Wort). *Hum Psychopharmacol* 2004;19:275-6. [View abstract.](#) **13021**
- Szegedi A, Kohnen R, Dienel A, Kieser M. Acute treatment of moderate to severe depression with hypericum extract WS 5570 (St John's wort): randomised controlled double blind non-inferiority trial versus paroxetine. *BMJ* 2005;330:503. [View abstract.](#) **13038**
- Lau WC, Carville DGM, Guyer KE, et al. St. John's Wort Enhances the Platelet Inhibitory Effect of Clopidogrel in Clopidogrel "Resistant" Healthy Volunteers. American College of Cardiology Annual Meeting, Orlando, FL 2005: Presentation 1043-129. **13099**
- Murphy PA, Kern SE, Stanczyk FZ, Westhoff CL. Interaction of St. John's Wort with oral contraceptives: effects on the pharmacokinetics of norethindrone and ethinyl estradiol, ovarian activity and breakthrough bleeding. *Contraception* 2005;71:402-8. [View abstract.](#) **13156**
- Linde K, Knuppel L. Large-scale observational studies of hypericum extracts in patients with depressive disorders - a systematic review. *Phytomedicine* 2005;12:148-57. [View abstract.](#) **13157**
- Linde K, Mulrow CD, Berner M, Egger M. St John's Wort for depression. *Cochrane Database Syst Rev* 2005;(3):CD000448. [View abstract.](#) **13158**
- Bryant SM, Kolodchak J. Serotonin syndrome resulting from an herbal detox cocktail. *Am J Emerg Med* 2004;22:625-6. [View abstract.](#) **14417**
- Kobak KA, Taylor LV, Bystritsky A, et al. St John's wort versus placebo in obsessive-compulsive disorder: results from a double-blind study. *Int Clin Psychopharmacol* 2005;20:299-304. [View abstract.](#) **14481**
- Barnes J, Barber N, Wheatley D, Williamson EM. A pilot randomised, open, uncontrolled, clinical study of two dosages of St John's wort (*Hypericum perforatum*) herb extract (LI-160) as an aid to motivational/behavioural support in smoking cessation. *Planta Med* 2006;72:378-82. [View abstract.](#) **14865**
- Dasgupta A, Hovanetz M, Olsen M, et al. Drug-herb interaction: effect of St John's wort on bioavailability and metabolism of procainamide in mice. *Arch Pathol Lab Med* 2007;131:1094-8. [View abstract.](#) **15037**
- Uebelhack R, Blohmer JU, Graubaum HJ, et al. Black cohosh and St. John's wort for climacteric complaints: a randomized trial. *Obstet Gynecol* 2006;107(2 Pt 1):247-55. [View abstract.](#) **15122**
- Dugoua JJ, Mills E, Perri D, Koren G. Safety and efficacy of St. John's wort (*hypericum*) during pregnancy and lactation. *Can J Clin Pharmacol* 2006;13:e268-76. [View abstract.](#) **15176**
- Jiang X, Blair EY, McLachlan AJ. Investigation of the effects of herbal medicines on warfarin response in healthy subjects: a population pharmacokinetic-pharmacodynamic modeling approach. *J Clin Pharmacol* 2006;46:1370-8. [View abstract.](#) **15544**
- Niederhofer H. St. John's wort may diminish methylphenidate's efficacy in treating patients suffering from attention deficit hyperactivity disorder. *Med Hypotheses* 2007;68:1189. [View abstract.](#) **15545**
- Karalapillai DC, Bellomo R. Convulsions associated with an overdose of St John's wort. *Med J Aust* 2007;186:213-4. [View abstract.](#) **15546**
- Bell EC, Ravis WR, Lloyd KB, Stokes TJ. Effects of St. John's wort supplementation on ibuprofen pharmacokinetics. *Ann Pharmacother* 2007;41:229-34. [View abstract.](#) **15547**

- Fogle RH, Murphy PA, Westhoff CL, Stanczyk FZ. Does St. John's wort interfere with the antiandrogenic effect of oral contraceptive pills? *Contraception* 2006;74:245-8. [View abstract](#). **15549**
- Obach RS. Inhibition of human cytochrome P450 enzymes by constituents of St. John's wort, an herbal preparation used in the treatment of depression. *J Pharmacol Exp Ther* 2000;294:88-95. [View abstract](#). **15893**
- Chung DJ, Kim HY, Park KH, et al. Black cohosh and St. John's wort (GYNO-Plus) for climacteric symptoms. *Yonsei Med J* 2007;48:289-94. [View abstract](#). **16893**
- Saito YA, Rey E, Almazar-Elder AE, et al. A randomized, double-blind, placebo-controlled trial of St. John's wort for treating irritable bowel syndrome. *Am J Gastroenterol* 2010;105:170-7. [View abstract](#). **17088**
- Booth JN, McGwin G. The association between self-reported cataracts and St. John's Wort. *Curr Eye Res* 2009;34:863-6. [View abstract](#). **17225**
- Samadi S, Khadivzadeh T, Emami A, et al. The effect of *Hypericum perforatum* on the wound healing and scar of cesarean. *J Altern Complement Med* 2010;16:113-7. [View abstract](#). **17405**
- Wang LS, Zhu B, Abd El-Aty A, et al. The influence of St. John's wort on CYP2C19 activity with respect to genotype. *J Clin Pharmacol* 2004;44:577-81. [View abstract](#). **17986**
- Weber W, Vander Stoep A, McCarty RL, et al. *Hypericum perforatum* (St John's wort) for attention-deficit/hyperactivity disorder in children and adolescents: a randomized controlled trial. *JAMA* 2008;299:2633-41. [View abstract](#). **22418**
- Lee, A., Minhas, R., Matsuda, N., Lam, M., and Ito, S. The safety of St. John's wort (*Hypericum perforatum*) during breastfeeding. *J Clin Psychiatry* 2003;64(8):966-968. [View abstract](#). **22419**
- Eich-Hochli, D., Oppliger, R., Golay, K. P., Baumann, P., and Eap, C. B. Methadone maintenance treatment and St. John's Wort - a case report. *Pharmacopsychiatry* 2003;36(1):35-37. **22421**
- Koupparis, L. S. Harmless herbs: a cause for concern? *Anaesthesia* 2000;55(1):101-102. [View abstract](#). **22422**
- Crowe, S. and McKeating, K. Delayed emergence and St. John's wort. *Anesthesiology* 2002;96(4):1025-1027. [View abstract](#). **22423**
- Smith M, Lin KM, and Zheng YP. PIII-89 an open trial of nifedipine-herb interactions: Nifedipine with St. John's wort, ginseng or ginkgo biloba. *Clin Pharm Ther* 2001;69:P86. **22424**
- Kawaguchi, A., Ohmori, M., Tsuruoka, S., Nishiki, K., Harada, K., Miyamori, I., Yano, R., Nakamura, T., Masada, M., and Fujimura, A. Drug interaction between St John's Wort and quazepam. *Br.J.Clin Pharmacol.* 2004;58(4):403-410. [View abstract](#). **22425**
- Dresser, G. K., Schwarz, U. I., Wilkinson, G. R., and Kim, R. B. Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects. *Clin Pharmacol Ther* 2003;73(1):41-50. [View abstract](#). **22427**
- Patel, J., Buddha, B., Dey, S., Pal, D., and Mitra, A. K. In vitro interaction of the HIV protease inhibitor ritonavir with herbal constituents: changes in P-gp and CYP3A4 activity. *Am.J.Ther.* 2004;11(4):262-277. [View abstract](#). **22431**

- Xu, H., Williams, K. M., Liauw, W. S., Murray, M., Day, R. O., and McLachlan, A. J. Effects of St John's wort and CYP2C9 genotype on the pharmacokinetics and pharmacodynamics of glimepiride. *Br.J.Pharmacol.* 2008;153(7):1579-1586. [View abstract.](#) **22432**
- Rengelshausen, J., Banfield, M., Riedel, K. D., Burhenne, J., Weiss, J., Thomsen, T., Walter-Sack, I., Haefeli, W. E., and Mikus, G. Opposite effects of short-term and long-term St John's wort intake on voriconazole pharmacokinetics. *Clin.Pharmacol Ther.* 2005;78(1):25-33. [View abstract.](#) **22435**
- Peebles, K. A., Baker, R. K., Kurz, E. U., Schneider, B. J., and Kroll, D. J. Catalytic inhibition of human DNA topoisomerase II alpha by hypericin, a naphthodianthrone from St. John's wort (*Hypericum perforatum*). *Biochem Pharmacol* 10-15-2001;62(8):1059-1070. [View abstract.](#) **22437**
- Tannergren, C., Engman, H., Knutson, L., Hedeland, M., Bondesson, U., and Lennernas, H. St John's wort decreases the bioavailability of R- and S-verapamil through induction of the first-pass metabolism. *Clin Pharmacol.Ther.* 2004;75(4):298-309. [View abstract.](#) **22440**
- Wang, L. S., Zhou, G., Zhu, B., Wu, J., Wang, J. G., Abd El-Aty, A. M., Li, T., Liu, J., Yang, T. L., Wang, D., Zhong, X. Y., and Zhou, H. H. St John's wort induces both cytochrome P450 3A4-catalyzed sulfoxidation and 2C19-dependent hydroxylation of omeprazole. *Clin Pharmacol.Ther.* 2004;75(3):191-197. [View abstract.](#) **22441**
- Hojo, Y., Echizenya, M., Ohkubo, T., and Shimizu, T. Drug interaction between St John's wort and zolpidem in healthy subjects. *J.Clin.Pharm.Ther.* 2011;36(6):711-715. [View abstract.](#) **35853**
- Briese V, Stammwitz U, Friede M, Henneicke-von Zepelin HH. Black cohosh with or without St. John's wort for symptom-specific climacteric treatment--results of a large-scale, controlled, observational study. *Maturitas* 2007;57:405-14. [View abstract.](#) **41482**
- van Die, M. D., Burger, H. G., Bone, K. M., Cohen, M. M., and Teede, H. J. *Hypericum perforatum* with *Vitex agnus-castus* in menopausal symptoms: a randomized, controlled trial. *Menopause.* 2009;16(1):156-163. [View abstract.](#) **48603**
- Izzo, A. A. and Ernst, E. Interactions between herbal medicines and prescribed drugs: an updated systematic review. *Drugs* 2009;69(13):1777-1798. [View abstract.](#) **70326**
- Schulz, H. U., Schurer, M., Bassler, D., and Weiser, D. Investigation of the bioavailability of hypericin, pseudohypericin, hyperforin and the flavonoids quercetin and isorhamnetin following single and multiple oral dosing of a hypericum extract containing tablet. *Arzneimittelforschung.* 2005;55(1):15-22. [View abstract.](#) **70349**
- Kasper, S. Treatment of seasonal affective disorder (SAD) with hypericum extract. *Pharmacopsychiatry* 1997;30 Suppl 2:89-93. [View abstract.](#) **76043**
- Grube, B., Walper, A., and Wheatley, D. St. John's Wort extract: efficacy for menopausal symptoms of psychological origin. *Adv Ther* 1999;16(4):177-186. [View abstract.](#) **76045**
- Di, Matteo, V, Di Giovanni, G., Di Mascio, M., and Esposito, E. Effect of acute administration of hypericum perforatum-CO2 extract on dopamine and serotonin release in the rat central nervous system. *Pharmacopsychiatry* 2000;33(1):14-18. [View abstract.](#) **76047**
- Barbenel, D. M., Yusufi, B., O'Shea, D., and Bench, C. J. Mania in a patient receiving testosterone replacement postorchidectomy taking St John's wort and sertraline. *J Psychopharmacol* 2000;14(1):84-86. [View abstract.](#) **76049**
- Wonnemann, M., Singer, A., and Muller, W. E. Inhibition of synaptosomal uptake of 3H-L-glutamate and 3H-GABA by hyperforin, a major constituent of St. John's Wort: the role of

amiloride sensitive sodium conductive pathways. *Neuropsychopharmacology* 2000;23(2):188-197. [View abstract](#).

76052

Greeson, J. M., Sanford, B., and Monti, D. A. St. John's wort (*Hypericum perforatum*): a review of the current pharmacological, toxicological, and clinical literature. *Psychopharmacology (Berl)* 2001;153(4):402-414. [View abstract](#).

76055

Nathan, P. J. *Hypericum perforatum* (St John's Wort): a non-selective reuptake inhibitor? A review of the recent advances in its pharmacology. *J Psychopharmacol.* 2001;15(1):47-54. [View abstract](#).

76056

Ratz, A. E., von Moos, M., and Drewe, J. [St. John's wort: a pharmaceutical with potentially dangerous interactions]. *Schweiz Rundsch.Med Prax.* 5-10-2001;90(19):843-849. [View abstract](#).

76057

Kalb, R., Trautmann-Sponsel, R. D., and Kieser, M. Efficacy and tolerability of hypericum extract WS 5572 versus placebo in mildly to moderately depressed patients. A randomized double-blind multicenter clinical trial. *Pharmacopsychiatry* 2001;34(3):96-103. [View abstract](#).

76061

Hunt, E. J., Lester, C. E., Lester, E. A., and Tackett, R. L. Effect of St. John's wort on free radical production. *Life Sci* 6-1-2001;69(2):181-190. [View abstract](#).

76062

Pietta, P., Gardana, C., and Pietta, A. Comparative evaluation of St. John's wort from different Italian regions. *Farmaco* 2001;56(5-7):491-496. [View abstract](#).

76064

Guzelcan, Y., Scholte, W. F., Assies, J., and Becker, H. E. [Mania during the use of a combination preparation with St. John's wort (*Hypericum perforatum*)]. *Ned.Tijdschr.Geneeskd.* 10-6-2001;145(40):1943-1945. [View abstract](#).

76066

Davidson, J. R. and Connor, K. M. St. John's wort in generalized anxiety disorder: three case reports. *J Clin Psychopharmacol* 2001;21(6):635-636. [View abstract](#).

76070

van Gorp, G., Meterissian, G. B., Haiek, L. N., McCusker, J., and Bellavance, F. St John's wort or sertraline? Randomized controlled trial in primary care. *Can Fam Physician* 2002;48:905-912. [View abstract](#).

76071

Lecrubier, Y., Clerc, G., Didi, R., and Kieser, M. Efficacy of St. John's wort extract WS 5570 in major depression: a double-blind, placebo-controlled trial. *Am J Psychiatry* 2002;159(8):1361-1366. [View abstract](#).

76072

Schempp, C. M., Winghofer, B., Muller, K., Schulte-Monting, J., Mannel, M., Schopf, E., and Simon, J. C. Effect of oral administration of *Hypericum perforatum* extract (St. John's Wort) on skin erythema and pigmentation induced by UVB, UVA, visible light and solar simulated radiation. *Phytother Res* 2003;17(2):141-146. [View abstract](#).

76073

Zullino, D. and Borgeat, F. Hypertension induced by St. John's Wort - a case report. *Pharmacopsychiatry* 2003;36(1):32. [View abstract](#).

76074

Degar, S., Prince, A. M., Pascual, D., Lavie, G., Levin, B., Mazur, Y., Lavie, D., Ehrlich, L. S., Carter, C., and Meruelo, D. Inactivation of the human immunodeficiency virus by hypericin: evidence for photochemical alterations of p24 and a block in uncoating. *AIDS Research and Human Retroviruses* 1992;8(11):1929-1936. [View abstract](#).

76075

Hostanska, K., Reichling, J., Bommer, S., Weber, M., and Saller, R. Hyperforin a constituent of St John's wort (*Hypericum perforatum* L.) extract induces apoptosis by triggering activation of caspases and with hypericin synergistically exerts cytotoxicity towards human malignant cell lines. *Eur.J Pharm Biopharm.* 2003;56(1):121-132. [View abstract](#).

76076

- Di Carlo, G., Nuzzo, I., Capasso, R., Sanges, M. R., Galdiero, E., Capasso, F., and Carratelli, C. R. Modulation of apoptosis in mice treated with Echinacea and St. John's wort. *Pharmacol Res* 2003;48(3):273-277. [View abstract](#). **76078**
- Kobak, K. A., Taylor, L., Futterer, R., and Warner, G. St. John's wort in generalized anxiety disorder: three more case reports. *J Clin Psychopharmacol*. 2003;23(5):531-532. [View abstract](#). **76079**
- Wright, C. W., Gott, M., Grayson, B., Hanna, M., Smith, A. G., Sunter, A., and Neill, J. C. Correlation of hyperforin content of *Hypericum perforatum* (St John's Wort) extracts with their effects on alcohol drinking in C57BL/6J mice: a preliminary study. *J Psychopharmacol*. 2003;17(4):403-408. [View abstract](#). **76081**
- Cui, Y., Ang, C. Y., Beger, R. D., Heinze, T. M., Hu, L., and Leakey, J. In vitro metabolism of hyperforin in rat liver microsomal systems. *Drug Metab Dispos*. 2004;32(1):28-34. [View abstract](#). **76084**
- Feisst, C. and Werz, O. Suppression of receptor-mediated Ca²⁺ mobilization and functional leukocyte responses by hyperforin. *Biochem Pharmacol* 4-15-2004;67(8):1531-1539. [View abstract](#). **76087**
- Werneke, U., Horn, O., and Taylor, D. M. How effective is St John's wort? The evidence revisited. *J Clin.Psychiatry* 2004;65(5):611-617. [View abstract](#). **76088**
- Roder, C., Schaefer, M., and Leucht, S. [Meta-analysis of effectiveness and tolerability of treatment of mild to moderate depression with St. John's Wort]. *Fortschr.Neurol.Psychiatr*. 2004;72(6):330-343. [View abstract](#). **76089**
- Muller, T., Mannel, M., Murck, H., and Rahlfs, V. W. Treatment of somatoform disorders with St. John's wort: a randomized, double-blind and placebo-controlled trial. *Psychosom.Med*. 2004;66(4):538-547. [View abstract](#). **76090**
- Gobbi, M., Moia, M., Funicello, M., Riva, A., Morazzoni, P., and Mennini, T. In vitro effects of the dicyclohexylammonium salt of hyperforin on interleukin-6 release in different experimental models. *Planta Med* 2004;70(7):680-682. [View abstract](#). **76092**
- Dona, M., Dell'Aica, I., Pezzato, E., Sartor, L., Calabrese, F., Della, Barbera M., Donella-Deana, A., Appendino, G., Borsarini, A., Caniato, R., and Garbisa, S. Hyperforin inhibits cancer invasion and metastasis. *Cancer Res* 9-1-2004;64(17):6225-6232. [View abstract](#). **76094**
- Trautmann-Sponsel, R. D. and Dienel, A. Safety of *Hypericum* extract in mildly to moderately depressed outpatients: a review based on data from three randomized, placebo-controlled trials. *J Affect Disord* 2004;82(2):303-307. [View abstract](#). **76098**
- Knuppel, L. and Linde, K. Adverse effects of St. John's Wort: a systematic review. *J Clin.Psychiatry* 2004;65(11):1470-1479. [View abstract](#). **76100**
- Zhou, C., Tabb, M. M., Sadatrafiei, A., Grun, F., Sun, A., and Blumberg, B. Hyperforin, the active component of St. John's wort, induces IL-8 expression in human intestinal epithelial cells via a MAPK-dependent, NF-kappaB-independent pathway. *J Clin.Immunol*. 2004;24(6):623-636. [View abstract](#). **76101**
- Kobak, K. A., Taylor, L. V., Warner, G., and Futterer, R. St. John's wort versus placebo in social phobia: results from a placebo-controlled pilot study. *J.Clin Psychopharmacol*. 2005;25(1):51-58. [View abstract](#). **76102**
- Winkler, C., Wirleitner, B., Schroecksnadel, K., Schennach, H., and Fuchs, D. St. John's wort (*Hypericum perforatum*) counteracts cytokine-induced tryptophan catabolism in vitro. *Biol.Chem* 2004;385(12):1197-1202. [View abstract](#).

- 76103**
- Pajonk, F., Scholber, J., and Fiebich, B. Hypericin-an inhibitor of proteasome function. *Cancer Chemother.Pharmacol* 2005;55(5):439-446. [View abstract.](#)
- 76104**
- Hicks, S. M., Walker, A. F., Gallagher, J., Middleton, R. W., and Wright, J. The significance of "nonsignificance" in randomized controlled studies: a discussion inspired by a double-blinded study on St. John's wort (*Hypericum perforatum* L.) for premenstrual symptoms. *J.Altern.Complement Med.* 2004;10(6):925-932. [View abstract.](#)
- 76105**
- Linde, K., Berner, M., Egger, M., and Mulrow, C. St John's wort for depression: meta-analysis of randomised controlled trials. *Br.J Psychiatry* 2005;186:99-107. [View abstract.](#)
- 76110**
- Simeon, J., Nixon, M. K., Milin, R., Jovanovic, R., and Walker, S. Open-label pilot study of St. John's wort in adolescent depression. *J Child Adolesc.Psychopharmacol.* 2005;15(2):293-301. [View abstract.](#)
- 76111**
- Nanayakkara, P. W., Meijboom, M., and Schouten, J. A. [Suicidal and aggressive thoughts as a result of taking a *Hypericum* preparation (St. John's wort)]. *Ned.Tijdschr.Geneeskd.* 6-11-2005;149(24):1347-1349. [View abstract.](#)
- 76113**
- Fava, M., Alpert, J., Nierenberg, A. A., Mischoulon, D., Otto, M. W., Zajecka, J., Murck, H., and Rosenbaum, J. F. A Double-blind, randomized trial of St John's wort, fluoxetine, and placebo in major depressive disorder. *J.Clin.Psychopharmacol.* 2005;25(5):441-447. [View abstract.](#)
- 76115**
- Demiroglu, Y. Z., Yeter, T. T., Boga, C., Ozdogu, H., Kizilkilic, E., Bal, N., Tuncer, I., and Arslan, H. Bone marrow necrosis: a rare complication of herbal treatment with *Hypericum perforatum* (St. John's wort). *Acta Medica.(Hradec.Kralove)* 2005;48(2):91-94. [View abstract.](#)
- 76119**
- Hudson, J. B., Lopez-Bazzocchi, I., and Towers, G. H. Antiviral activities of hypericin. *Antiviral Res* 1991;15(2):101-112. [View abstract.](#)
- 76120**
- Gastpar, M., Singer, A., and Zeller, K. Comparative efficacy and safety of a once-daily dosage of hypericum extract STW3-VI and citalopram in patients with moderate depression: a double-blind, randomised, multicentre, placebo-controlled study. *Pharmacopsychiatry* 2006;39(2):66-75. [View abstract.](#)
- 76121**
- Lopez-Bazzocchi, I., Hudson, J. B., and Towers, G. H. Antiviral activity of the photoactive plant pigment hypericin. *Photochem.Photobiol.* 1991;54(1):95-98. [View abstract.](#)
- 76124**
- Schinazi, R. F., Chu, C. K., Babu, J. R., Oswald, B. J., Saalman, V., Cannon, D. L., Eriksson, B. F., and Nasr, M. Anthraquinones as a new class of antiviral agents against human immunodeficiency virus. *Antiviral Res* 1990;13(5):265-272. [View abstract.](#)
- 76125**
- Tang, J., Colacino, J. M., Larsen, S. H., and Spitzer, W. Virucidal activity of hypericin against enveloped and non-enveloped DNA and RNA viruses. *Antiviral Res* 1990;13(6):313-325. [View abstract.](#)
- 76127**
- Carpenter, S. and Kraus, G. A. Photosensitization is required for inactivation of equine infectious anemia virus by hypericin. *Photochem.Photobiol.* 1991;53(2):169-174. [View abstract.](#)
- 76128**
- Cappuzzo, K. A. Herbal product use in a patient with polypharmacy. *Consult Pharm.* 2006;21(11):911-915. [View abstract.](#)
- 76132**
- Papakostas, G. I., Crawford, C. M., Scalia, M. J., and Fava, M. Timing of clinical improvement and symptom resolution in the treatment of major depressive disorder. A replication of findings with the use of a double-blind, placebo-controlled trial of *Hypericum perforatum* versus fluoxetine. *Neuropsychobiology* 2007;56(2-3):132-137. [View abstract.](#)

- 76133**
- Sardella, A., Lodi, G., Demarosi, F., Tarozzi, M., Canegallo, L., and Carrassi, A. Hypericum perforatum extract in burning mouth syndrome: a randomized placebo-controlled study. *J.Oral Pathol.Med.* 2008;37(7):395-401. [View abstract.](#)
- 76135**
- Etogo-Asse, F., Boemer, F., Sempoux, C., and Geubel, A. Acute hepatitis with prolonged cholestasis and disappearance of interlobular bile ducts following tibolone and Hypericum perforatum (St. John's wort). Case of drug interaction? *Acta Gastroenterol.Belg.* 2008;71(1):36-38. [View abstract.](#)
- 76137**
- Andreescu, C., Mulsant, B. H., and Emanuel, J. E. Complementary and alternative medicine in the treatment of bipolar disorder--a review of the evidence. *J.Affect.Disord.* 2008;110(1-2):16-26. [View abstract.](#)
- 76140**
- Kasper, S., Volz, H. P., Moller, H. J., Dienel, A., and Kieser, M. Continuation and long-term maintenance treatment with Hypericum extract WS 5570 after recovery from an acute episode of moderate depression--a double-blind, randomized, placebo controlled long-term trial. *Eur.Neuropsychopharmacol.* 2008;18(11):803-813. [View abstract.](#)
- 76143**
- Linde, K., Berner, M. M., and Kriston, L. St John's wort for major depression. *Cochrane.Database.Syst.Rev.* 2008;(4):CD000448. [View abstract.](#)
- 76144**
- Rahimi, R., Nikfar, S., and Abdollahi, M. Efficacy and tolerability of Hypericum perforatum in major depressive disorder in comparison with selective serotonin reuptake inhibitors: a meta-analysis. *Prog.Neuropsychopharmacol.Biol.Psychiatry* 2-1-2009;33(1):118-127. [View abstract.](#)
- 76146**
- Al-Akoum, M., Maunsell, E., Verreault, R., Provencher, L., Otis, H., and Dodin, S. Effects of Hypericum perforatum (St. John's wort) on hot flashes and quality of life in perimenopausal women: a randomized pilot trial. *Menopause.* 2009;16(2):307-314. [View abstract.](#)
- 76148**
- Brattstrom, A. Long-term effects of St. John's wort (Hypericum perforatum) treatment: a 1-year safety study in mild to moderate depression. *Phytomedicine.* 2009;16(4):277-283. [View abstract.](#)
- 76150**
- Canning, S., Waterman, M., Orsi, N., Ayres, J., Simpson, N., and Dye, L. The efficacy of Hypericum perforatum (St John's wort) for the treatment of premenstrual syndrome: a randomized, double-blind, placebo-controlled trial. *CNS.Drugs* 2010;24(3):207-225. [View abstract.](#)
- 76151**
- Melzer, J., Brignoli, R., Keck, M. E., and Saller, R. A hypericum extract in the treatment of depressive symptoms in outpatients: an open study. *Forsch.Komplementmed.* 2010;17(1):7-14. [View abstract.](#)
- 76153**
- Kasper, S., Gastpar, M., Moller, H. J., Muller, W. E., Volz, H. P., Dienel, A., and Kieser, M. Better tolerability of St. John's wort extract WS 5570 compared to treatment with SSRIs: a reanalysis of data from controlled clinical trials in acute major depression. *Int.Clin.Psychopharmacol.* 2010;25(4):204-213. [View abstract.](#)
- 76154**
- Berlanda, J., Kiesslich, T., Engelhardt, V., Krammer, B., and Plaetzer, K. Comparative in vitro study on the characteristics of different photosensitizers employed in PDT. *J.Photochem.Photobiol.B* 9-2-2010;100(3):173-180. [View abstract.](#)
- 76156**
- Bancirova, M. and Lasovsky, J. The photodynamic effect: the comparison of chemiexcitation by luminol and phthalhydrazide. *Luminescence.* 2011;26(6):410-415. [View abstract.](#)
- 76159**
- Ghazanfarpour, M., Kaviani, M., Asadi, N., Ghaffarpasand, F., Ziyadlou, S., Tabatabaee, H. R., and Dehghankhalili, M. Hypericum perforatum for the treatment of premenstrual syndrome. *Int.J.Gynaecol.Obstet.* 2011;113(1):84-85. [View abstract.](#)

- 76160
Couldwell, W. T., Surnock, A. A., Tobia, A. J., Cabana, B. E., Stillerman, C. B., Forsyth, P. A., Appley, A. J., Spence, A. M., Hinton, D. R., and Chen, T. C. A phase 1/2 study of orally administered synthetic hypericin for treatment of recurrent malignant gliomas. *Cancer* 11-1-2011;117(21):4905-4915. [View abstract](#).
- 76163
Van Strater, A. C. and Bogers, J. P. Interaction of St John's wort (*Hypericum perforatum*) with clozapine. *Int.Clin.Psychopharmacol.* 2012;27(2):121-124. [View abstract](#).
- 76164
Clewell, A., Barnes, M., Endres, J. R., Ahmed, M., and Ghambeer, D. K. Efficacy and tolerability assessment of a topical formulation containing copper sulfate and hypericum perforatum on patients with herpes skin lesions: a comparative, randomized controlled trial. *J.Drugs Dermatol.* 2012;11(2):209-215. [View abstract](#).
- 76165
Okpanyi, S. N., Lidzba, H., Scholl, B. C., and Miltenburger, H. G. [Genotoxicity of a standardized *Hypericum* extract]. *Arzneimittelforschung.* 1990;40(8):851-855. [View abstract](#).
- 76167
Najafizadeh, P., Hashemian, F., Mansouri, P., Farshi, S., Surmaghi, M. S., and Chalangari, R. The evaluation of the clinical effect of topical St Johns wort (*Hypericum perforatum* L.) in plaque type psoriasis vulgaris: a pilot study. *Australas.J.Dermatol.* 2012;53(2):131-135. [View abstract](#).
- 76168
Lavie, G., Valentine, F., Levin, B., Mazur, Y., Gallo, G., Lavie, D., Weiner, D., and Meruelo, D. Studies of the mechanisms of action of the antiretroviral agents hypericin and pseudohypericin. *Proc Natl.Acad.Sci U.S.A* 1989;86(15):5963-5967. [View abstract](#).
- 76169
Meruelo, D., Lavie, G., and Lavie, D. Therapeutic agents with dramatic antiretroviral activity and little toxicity at effective doses: aromatic polycyclic diones hypericin and pseudohypericin. *Proc.Natl.Acad.Sci U.S.A* 1988;85(14):5230-5234. [View abstract](#).
- 76170
Suzuki, O., Katsumata, Y., Oya, M., Bladt, S., and Wagner, H. Inhibition of monoamine oxidase by hypericin. *Planta Med* 1984;50(3):272-274. [View abstract](#).
- 76173
Couldwell, W. T., Gopalakrishna, R., Hinton, D. R., He, S., Weiss, M. H., Law, R. E., Apuzzo, M. L., and Law, R. E. Hypericin: a potential antiglioma therapy. *Neurosurgery* 1994;35(4):705-710. [View abstract](#).
- 76174
Harrer, G., Hubner, W. D., and Podzuweit, H. Effectiveness and tolerance of the hypericum extract LI 160 compared to maprotiline: a multicenter double-blind study. *J.Geriatr.Psychiatry Neurol.* 1994;7 Suppl 1:S24-S28. [View abstract](#).
- 76175
Martinez, B., Kasper, S., Ruhrmann, S., and Moller, H. J. *Hypericum* in the treatment of seasonal affective disorders. *J Geriatr.Psychiatry Neurol.* 1994;7 Suppl 1:S29-S33. [View abstract](#).
- 76179
Staffeldt, B., Kerb, R., Brockmoller, J., Ploch, M., and Roots, I. Pharmacokinetics of hypericin and pseudohypericin after oral intake of the hypericum perforatum extract LI 160 in healthy volunteers. *J Geriatr.Psychiatry Neurol.* 1994;7 Suppl 1:S47-S53. [View abstract](#).
- 76180
Thiede, H. M. and Walper, A. Inhibition of MAO and COMT by hypericum extracts and hypericin. *J Geriatr.Psychiatry Neurol.* 1994;7 Suppl 1:S54-S56. [View abstract](#).
- 76181
Bladt, S. and Wagner, H. Inhibition of MAO by fractions and constituents of hypericum extract. *J Geriatr.Psychiatry Neurol.* 1994;7 Suppl 1:S57-S59. [View abstract](#).
- 76183
Thiele, B., Brink, I., and Ploch, M. Modulation of cytokine expression by hypericum extract. *J Geriatr.Psychiatry Neurol.* 1994;7 Suppl 1:S60-S62. [View abstract](#).
- 76184

- Hudson, J. B., Graham, E. A., and Towers, G. H. Antiviral assays on phytochemicals: the influence of reaction parameters. *Planta Med.* 1994;60(4):329-332. [View abstract.](#) **76186**
- Cohen, P. A., Hudson, J. B., and Towers, G. H. Antiviral activities of anthraquinones, bianthrone and hypericin derivatives from lichens. *Experientia* 2-15-1996;52(3):180-183. [View abstract.](#) **76187**
- Kerb, R., Brockmoller, J., Staffeldt, B., Ploch, M., and Roots, I. Single-dose and steady-state pharmacokinetics of hypericin and pseudohypericin. *Antimicrob. Agents Chemother.* 1996;40(9):2087-2093. [View abstract.](#) **76188**
- Müller WE, Rolli, M., Schafer, C., and Hafner, U. Effects of hypericum extract (LI 160) in biochemical models of antidepressant activity. *Pharmacopsychiatry* 1997;30 Suppl 2:102-107. [View abstract.](#) **76189**
- Cott, J. M. In vitro receptor binding and enzyme inhibition by *Hypericum perforatum* extract. *Pharmacopsychiatry* 1997;30 Suppl 2:108-112. [View abstract.](#) **76191**
- Butterweck, V., Wall, A., Lieflander-Wulf, U., Winterhoff, H., and Nahrstedt, A. Effects of the total extract and fractions of *Hypericum perforatum* in animal assays for antidepressant activity. *Pharmacopsychiatry* 1997;30 Suppl 2:117-124. [View abstract.](#) **76192**
- Nahrstedt, A. and Butterweck, V. Biologically active and other chemical constituents of the herb of *Hypericum perforatum* L. *Pharmacopsychiatry* 1997;30 Suppl 2:129-134. [View abstract.](#) **76194**
- Bhattacharya, S. K., Chakrabarti, A., and Chatterjee, S. S. Activity profiles of two hyperforin-containing hypericum extracts in behavioral models. *Pharmacopsychiatry* 1998;31 Suppl 1:22-29. [View abstract.](#) **76195**
- Biber, A., Fischer, H., Romer, A., and Chatterjee, S. S. Oral bioavailability of hyperforin from hypericum extracts in rats and human volunteers. *Pharmacopsychiatry* 1998;31 Suppl 1:36-43. [View abstract.](#) **76221**
- Leclercq Y. Clinical significance of hyperforin for the efficacy of *Hypericum* extracts on depressive disorders of different severities. *Eur Neuropsychopharmacol* 2001;11:105-106. **76243**
- Leuschner G. Preclinical toxicology profile of *Hypericum* extract LI 160. *Phytomedicine* 1996;supplement 1:104. **76245**
- Sultana D, Peindl KS Wisner KL. Rash associated with St. John's wort treatment in premenstrual dysphoric disorder. *Arch Women Ment Health* 2000;3:99-101. **76249**
- Demisch L, Holz J, Gollnik B, and et al. Identification of selective MAO-type-A inhibitors in *Hypericum perforatum* L. (*Hyperforat*). *Pharmacopsychiat.* 1989;22:194. **76251**
- Wood S, Huffman J, Weber N, and et al. Antiviral activity of naturally occurring anthraquinones and anthraquinone derivatives. *Planta Med* 1990;56:651-652. **76253**
- Bombardelli E and Morazzoni P. *Hypericum perforatum*. *Fitoterapia* 1995;66(1):43-68. **76254**
- Panossian AG, Gabrielian E, Manvelian V, and et al. Immunosuppressive effects of hypericin on stimulated human leukocytes: inhibition of the arachidonic acid release, leukotriene B **76266**
- Bernd A, Ramirez-Bosca A, Kippenberger S, and et al. Phototoxic effects of *Hypericum* extract in cultures of human keratinocytes compared with those of psoralen. *Photochem Photobiol* 1999;2(69):218-221. **76268**

- Woelk H, Burkard G, and Grunwald J. Nutzen und Risikobewertung des Hypericum-extraktes LI 160 auf der Basis einer Drug-Monitoring-Studie mit 3250 Patienten. *Nervenheilkunde* 1993;12:308-313. **76269**
- Schakau D, Hiller K, Schultz-Zehden W, and et al. Risk/benefit profile of St. John's wort extract: STEI 300 in 2404 patients with various degrees of psychiatric disturbance. *Psychopharmakotherapie* 1996;3:116-122. **76270**
- Laird RD and Webb M. Psychotic episode during use of St John's wort. *J Herbal Pharmacother* 2001;1(2):81-87. **76271**
- Schrader E, Meier B, and Brattstrom A. Hypericum treatment of mild-moderate depression in a placebo-controlled study. A prospective, double-blind, randomized, placebo-controlled, multicentre study. *Human Psychopharm* 1998;13:163-169. **76273**
- Chatterjee SS, Bhattacharya SK, Singer A, and et al. Hyperforin inhibits synaptosomal uptake of neurotransmitters in vitro and shows antidepressant activity in vivo. *Pharmazie* 1998;53(3):9. **76277**
- Panijel M. [Treatment of moderately severe anxiety states]. *Therapiewoche* 1985;35(41):4659-4668. **89660**
- Dolton MJ, Mikus G, Weiss J, et al. Understanding variability with voriconazole using a population pharmacokinetic approach: implications for optimal dosing. *J Antimicrob Chemother* 2014;69(6):1633-41. [View abstract](#). **89661**
- Goey AK, Meijerman I, Rosing H, et al. The effect of St John's wort on the pharmacokinetics of docetaxel. *Clin Pharmacokinet* 2014;53(1):103-10. [View abstract](#). **89662**
- Lei HP, Yu XY, Xie HT, et al. Effect of St. John's wort supplementation on the pharmacokinetics of bupropion in healthy male Chinese volunteers. *Xenobiotica* 2010;40(4):275-81. [View abstract](#). **89663**
- Peltoniemi MA, Saari TI, Hagelberg NM, et al. St John's wort greatly decreases the plasma concentrations of oral S-ketamine. *Fundam Clin Pharmacol* 2012;26(6):743-50. [View abstract](#). **89664**
- Gurok MG, Mermi O, Kilic F, et al. Psychotic episode induced by St. John's wort (*Hypericum perforatum*): a case report. *J Mood Dis* 2014;4(1):38-40. **89665**
- Yildirim O, Canan F. A case of panic attack induced by St John's wort. *Prim Care Companion CNS Disord* 2013;15(1). pii: PCC.12I01453. [View abstract](#). **89666**
- Abdali K, Khajehei M, Tabatabaee HR. Effect of St John's wort on severity, frequency, and duration of hot flashes in premenopausal, perimenopausal and postmenopausal women: a randomized, double-blind, placebo-controlled study. *Menopause* 2010;17(2):326-31. [View abstract](#). **89667**
- Mirzaei MG, Sewell RDE, Kheiri S, Refieian-Kopaei M. A clinical trial of the effect of St. John's wort on migraine headaches in patients receiving sodium valproate. *J Med Plants Res* 2012;6(9):1519-23. **89668**
- Niederhofer H. St. John's wort may improve some symptoms of attention-deficit hyperactivity disorder. *Nat Prod Res* 2010;24(3):203-5. [View abstract](#). **89669**
- Pakseresht S, Boustani H, Azemi ME, et al. Evaluation of pharmaceutical products of St. John's wort efficacy added on tricyclic antidepressants in treating major depressive disorder: a double blind randomized control trial. *Jundishapur J Nat Pharm Prod* 2012;7(3):106-10. [View abstract](#). **89670**

Raak C, Büssing A, Gassmann G, et al. A systematic review and meta-analysis on the use of *Hypericum perforatum* (St. John's wort) for pain conditions in dental practice. *Homeopathy* 2012;101(4):204-10. [View abstract](#).

89671

Trana C, Toth G, Wijns W, Barbato E. St. John's Wort in patients non-responders to clopidogrel undergoing percutaneous coronary intervention: a single-center randomized open-label trial (St. John's Trial). *J Cardiovasc Transl Res* 2013;6(3):411-4. [View abstract](#).